A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings.

ambulatory glucose profile composite metric continuous glucose monitor diabetes glycemia risk index hyperglycemia hypoglycemia time in range

Journal

Journal of diabetes science and technology
ISSN: 1932-2968
Titre abrégé: J Diabetes Sci Technol
Pays: United States
ID NLM: 101306166

Informations de publication

Date de publication:
09 2023
Historique:
medline: 4 9 2023
pubmed: 30 3 2022
entrez: 29 3 2022
Statut: ppublish

Résumé

A composite metric for the quality of glycemia from continuous glucose monitor (CGM) tracings could be useful for assisting with basic clinical interpretation of CGM data. We assembled a data set of 14-day CGM tracings from 225 insulin-treated adults with diabetes. Using a balanced incomplete block design, 330 clinicians who were highly experienced with CGM analysis and interpretation ranked the CGM tracings from best to worst quality of glycemia. We used principal component analysis and multiple regressions to develop a model to predict the clinician ranking based on seven standard metrics in an Ambulatory Glucose Profile: very low-glucose and low-glucose hypoglycemia; very high-glucose and high-glucose hyperglycemia; time in range; mean glucose; and coefficient of variation. The analysis showed that clinician rankings depend on two components, one related to hypoglycemia that gives more weight to very low-glucose than to low-glucose and the other related to hyperglycemia that likewise gives greater weight to very high-glucose than to high-glucose. These two components should be calculated and displayed separately, but they can also be combined into a single Glycemia Risk Index (GRI) that corresponds closely to the clinician rankings of the overall quality of glycemia (r = 0.95). The GRI can be displayed graphically on a GRI Grid with the hypoglycemia component on the horizontal axis and the hyperglycemia component on the vertical axis. Diagonal lines divide the graph into five zones (quintiles) corresponding to the best (0th to 20th percentile) to worst (81st to 100th percentile) overall quality of glycemia. The GRI Grid enables users to track sequential changes within an individual over time and compare groups of individuals. The GRI is a single-number summary of the quality of glycemia. Its hypoglycemia and hyperglycemia components provide actionable scores and a graphical display (the GRI Grid) that can be used by clinicians and researchers to determine the glycemic effects of prescribed and investigational treatments.

Sections du résumé

BACKGROUND
A composite metric for the quality of glycemia from continuous glucose monitor (CGM) tracings could be useful for assisting with basic clinical interpretation of CGM data.
METHODS
We assembled a data set of 14-day CGM tracings from 225 insulin-treated adults with diabetes. Using a balanced incomplete block design, 330 clinicians who were highly experienced with CGM analysis and interpretation ranked the CGM tracings from best to worst quality of glycemia. We used principal component analysis and multiple regressions to develop a model to predict the clinician ranking based on seven standard metrics in an Ambulatory Glucose Profile: very low-glucose and low-glucose hypoglycemia; very high-glucose and high-glucose hyperglycemia; time in range; mean glucose; and coefficient of variation.
RESULTS
The analysis showed that clinician rankings depend on two components, one related to hypoglycemia that gives more weight to very low-glucose than to low-glucose and the other related to hyperglycemia that likewise gives greater weight to very high-glucose than to high-glucose. These two components should be calculated and displayed separately, but they can also be combined into a single Glycemia Risk Index (GRI) that corresponds closely to the clinician rankings of the overall quality of glycemia (r = 0.95). The GRI can be displayed graphically on a GRI Grid with the hypoglycemia component on the horizontal axis and the hyperglycemia component on the vertical axis. Diagonal lines divide the graph into five zones (quintiles) corresponding to the best (0th to 20th percentile) to worst (81st to 100th percentile) overall quality of glycemia. The GRI Grid enables users to track sequential changes within an individual over time and compare groups of individuals.
CONCLUSION
The GRI is a single-number summary of the quality of glycemia. Its hypoglycemia and hyperglycemia components provide actionable scores and a graphical display (the GRI Grid) that can be used by clinicians and researchers to determine the glycemic effects of prescribed and investigational treatments.

Identifiants

pubmed: 35348391
doi: 10.1177/19322968221085273
pmc: PMC10563532
doi:

Substances chimiques

Blood Glucose 0
Glucose IY9XDZ35W2

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural Research Support, U.S. Gov't, P.H.S. Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

1226-1242

Subventions

Organisme : NIDDK NIH HHS
ID : P30 DK045735
Pays : United States
Organisme : NIDDK NIH HHS
ID : K23 DK123384
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001855
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000130
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK111024
Pays : United States
Organisme : FDA HHS
ID : P50 FD006425
Pays : United States
Organisme : CSRD VA
ID : I01 CX001825
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK098722
Pays : United States

Références

Behav Res Methods. 2020 Aug;52(4):1459-1468
pubmed: 31823224
J Diabetes Sci Technol. 2015 Jan;9(1):56-62
pubmed: 25316714
J Diabetes Sci Technol. 2013 Mar 01;7(2):562-78
pubmed: 23567014
Diabetes Care. 2021 Nov;44(11):2589-2625
pubmed: 34593612
Biochim Biophys Acta Mol Basis Dis. 2021 Aug 1;1867(8):166148
pubmed: 33892081
BMJ. 2007 Apr 14;334(7597):786
pubmed: 17403713
JAMA. 2021 Jun 8;325(22):2273-2284
pubmed: 34077502
JAMA. 2017 Jan 24;317(4):371-378
pubmed: 28118453
Diabetes Technol Ther. 2009 Jun;11 Suppl 1:S55-67
pubmed: 19469679
Diabetes Spectr. 2021 May;34(2):109-118
pubmed: 34149251
Diabetes Technol Ther. 2021 Oct;23(10):692-704
pubmed: 34086495
Diabetes Care. 2017 Dec;40(12):1631-1640
pubmed: 29162583
Diabetes Care. 1997 Nov;20(11):1655-8
pubmed: 9353603
Ann Intern Med. 2017 Sep 19;167(6):365-374
pubmed: 28828487
J Diabetes Sci Technol. 2022 Jan;16(1):3-6
pubmed: 34711063
Diabetes Technol Ther. 2020 Aug;22(8):613-622
pubmed: 32069094
Diabetes Care. 2022 Jan 1;45(Suppl 1):S83-S96
pubmed: 34964868
N Engl J Med. 2019 Oct 31;381(18):1707-1717
pubmed: 31618560
Nat Rev Endocrinol. 2017 Jul;13(7):425-436
pubmed: 28304392
J Stat Softw. 2010;33(1):1-22
pubmed: 20808728
Diabetes Technol Ther. 2018 May;20(5):325-334
pubmed: 29792750
Diabetes Care. 2017 Apr;40(4):538-545
pubmed: 28209654
Diabetes Care. 1998 Nov;21(11):1870-5
pubmed: 9802735
Diabetes Care. 2019 Aug;42(8):1593-1603
pubmed: 31177185

Auteurs

David C Klonoff (DC)

Diabetes Research Institute, Mills-Peninsula Medical Center, San Mateo, CA, USA.

Jing Wang (J)

Florida State University College of Nursing, Tallahassee, FL, USA.

David Rodbard (D)

Biomedical Informatics Consultants LLC, Potomac, MD, USA.

Michael A Kohn (MA)

University of California, San Francisco, San Francisco, CA, USA.

Chengdong Li (C)

Florida State University College of Nursing, Tallahassee, FL, USA.

Dorian Liepmann (D)

University of California, Berkeley, Berkeley, CA, USA.

David Kerr (D)

Sansum Diabetes Research Institute, Santa Barbara, CA, USA.

David Ahn (D)

Hoag Memorial Hospital Presbyterian, Newport Beach, CA, USA.

Anne L Peters (AL)

University of Southern California, Los Angeles, CA, USA.

Guillermo E Umpierrez (GE)

Emory University, Atlanta, GA, USA.

Jane Jeffrie Seley (JJ)

Weill Cornell Medicine, New York, NY, USA.

Nicole Y Xu (NY)

Diabetes Technology Society, Burlingame, CA, USA.

Kevin T Nguyen (KT)

Diabetes Technology Society, Burlingame, CA, USA.

Gregg Simonson (G)

International Diabetes Center, Minneapolis, MN, USA.

Michael S D Agus (MSD)

Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.

Mohammed E Al-Sofiani (ME)

King Saud University, Riyadh, Saudi Arabia.
Johns Hopkins University, Baltimore, MD, USA.

Gustavo Armaiz-Pena (G)

UT Health San Antonio, San Antonio, TX, USA.

Timothy S Bailey (TS)

AMCR Institute, Escondido, CA, USA.

Ananda Basu (A)

University of Virginia, Charlottesville, VA, USA.

Tadej Battelino (T)

Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.

Sewagegn Yeshiwas Bekele (SY)

Addis Ababa University, Addis Ababa, Ethiopia.

Pierre-Yves Benhamou (PY)

Centre Hospitalier Universitaire de Grenoble, Grenoble, France.

B Wayne Bequette (BW)

Rensselaer Polytechnic Institute, Troy, NY, USA.

Thomas Blevins (T)

Texas Diabetes and Endocrinology, Austin, TX, USA.

Marc D Breton (MD)

University of Virginia, Charlottesville, VA, USA.

Jessica R Castle (JR)

Oregon Health & Science University, Portland, OR, USA.

James Geoffrey Chase (JG)

University of Canterbury, Christchurch, New Zealand.

Kong Y Chen (KY)

National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA.

Pratik Choudhary (P)

University of Leicester, Leicester, UK.

Mark A Clements (MA)

Children's Mercy Hospital, Kansas City, MO, USA.

Kelly L Close (KL)

Close Concerns, San Francisco, CA, USA.

Curtiss B Cook (CB)

Mayo Clinic Arizona, Scottsdale, AZ, USA.

Thomas Danne (T)

Diabetes Center Auf der Bult, Hannover Medical School, Hannover, Germany.

Francis J Doyle (FJ)

Harvard University, Cambridge, MA, USA.

Angela Drincic (A)

University of Nebraska, Omaha, NE, USA.

Kathleen M Dungan (KM)

The Ohio State University, Columbus, OH, USA.

Steven V Edelman (SV)

University of California, San Diego, San Diego, CA, USA.

Niels Ejskjaer (N)

Steno Diabetes Center North Denmark, Aalborg University Hospital, Aalborg, Denmark.

Juan C Espinoza (JC)

Children's Hospital Los Angeles, University of Southern California, Los Angeles, CA, USA.

Gregory P Forlenza (GP)

Barbara Davis Center for Diabetes, University of Colorado, Aurora, CO, USA.

Guido Freckmann (G)

Institute for Diabetes-Technology GmbH, Ulm, Germany.

Rodolfo J Galindo (RJ)

Emory University, Atlanta, GA, USA.

Ana Maria Gomez (AM)

Pontificia Universidad Javeriana, Bogotá, Colombia.

Hanna A Gutow (HA)

Close Concerns, San Francisco, CA, USA.

Lutz Heinemann (L)

Science Consulting in Diabetes GmbH, Kaarst, Germany.

Irl B Hirsch (IB)

University of Washington, Seattle, WA, USA.

Thanh D Hoang (TD)

Walter Reed National Military Medical Center, Bethesda, MD, USA.

Roman Hovorka (R)

University of Cambridge, Cambridge, UK.

Johan H Jendle (JH)

Örebro University, Örebro, Sweden.

Linong Ji (L)

Peking University People's Hospital, Peking University Diabetes Center, Beijing, China.

Michael Joubert (M)

Caen University Hospital, Caen, France.

Suneil K Koliwad (SK)

University of California, San Francisco, San Francisco, CA, USA.

Rayhan A Lal (RA)

Stanford University, Stanford, CA, USA.

M Cecilia Lansang (MC)

Cleveland Clinic, Cleveland, OH, USA.
Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA.

Wei-An Andy Lee (WA)

LAC + USC Medical Center, Los Angeles County Department of Health Service, Los Angeles, CA, USA.

Lalantha Leelarathna (L)

Manchester University NHS Foundation Trust and The University of Manchester, Manchester, UK.

Lawrence A Leiter (LA)

Li Ka Shing Knowledge Institute, St. Michael's Hospital and University of Toronto, Toronto, ON, Canada.

Marcus Lind (M)

University of Gothenburg, Gothenburg, Sweden.

Michelle L Litchman (ML)

The University of Utah College of Nursing, Salt Lake City, UT, USA.

Julia K Mader (JK)

Medical University of Graz, Graz, Austria.

Katherine M Mahoney (KM)

Close Concerns, San Francisco, CA, USA.

Boris Mankovsky (B)

National Healthcare University of Ukraine, Kiev, Ukraine.

Umesh Masharani (U)

University of California, San Francisco, San Francisco, CA, USA.

Nestoras N Mathioudakis (NN)

Johns Hopkins University, Baltimore, MD, USA.

Alexander Mayorov (A)

Endocrinology Research Centre, Moscow, Russian Federation.

Jordan Messler (J)

Morton Plant Hospital, Clearwater, FL, USA.

Joshua D Miller (JD)

Stony Brook University, Stony Brook, NY, USA.

Viswanathan Mohan (V)

Dr. Mohan's Diabetes Specialities Centre, Chennai, India.
Madras Diabetes Research Foundation, Chennai, India.

James H Nichols (JH)

Vanderbilt University Medical Center, Nashville, TN, USA.

Kirsten Nørgaard (K)

Steno Diabetes Center Copenhagen, Herlev, Denmark.

David N O'Neal (DN)

University of Melbourne, Melbourne, VIC, Australia.

Francisco J Pasquel (FJ)

Emory University, Atlanta, GA, USA.

Athena Philis-Tsimikas (A)

Scripps Whittier Diabetes Institute, San Diego, CA, USA.

Thomas Pieber (T)

Medical University of Graz, Graz, Austria.

Moshe Phillip (M)

Institute for Endocrinology and Diabetes, Schneider Children's Medical Center of Israel and Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel.

William H Polonsky (WH)

Behavioral Diabetes Institute, San Diego, CA, USA.

Rodica Pop-Busui (R)

University of Michigan, Ann Arbor, MI, USA.

Gerry Rayman (G)

Ipswich Hospital, East Suffolk and North Essex Foundation Trust and University of East Anglia, Ipswich, UK.

Eun-Jung Rhee (EJ)

Kangbuk Samsung Hospital, Sungkyunkwan University, Seoul, Korea.

Steven J Russell (SJ)

Massachusetts General Hospital Diabetes Research Center, Boston, MA, USA.

Viral N Shah (VN)

Barbara Davis Center for Diabetes, University of Colorado, Aurora, CO, USA.

Jennifer L Sherr (JL)

Yale University, New Haven, CT, USA.

Koji Sode (K)

The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
North Carolina State University, Raleigh, NC, USA.

Elias K Spanakis (EK)

University of Maryland, Baltimore, MD, USA.

Deborah J Wake (DJ)

The University of Edinburgh, Edinburgh, UK.

Kayo Waki (K)

The University of Tokyo, Tokyo, Japan.

Amisha Wallia (A)

Northwestern University, Chicago, IL, USA.

Melissa E Weinberg (ME)

California Pacific Medical Center, San Francisco, CA, USA.

Howard Wolpert (H)

Boston Medical Center, Boston, MA, USA.

Eugene E Wright (EE)

Charlotte AHEC, Charlotte, NC, USA.

Mihail Zilbermint (M)

Johns Hopkins University, Baltimore, MD, USA.
Johns Hopkins Community Physicians, Bethesda, MD, USA.

Boris Kovatchev (B)

University of Virginia, Charlottesville, VA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH